In vivo α-hydroxylation of a 2-alkylindole antagonist of the OXE receptor for the eosinophil chemoattractant 5-oxo-6,8,11,14-eicosatetraenoic acid in monkeys

• Published in: Biochemical pharmacology 2017-08, Vol.138, p.107-118
• Main Authors: Chourey, Shishir, Ye, Qiuji, Reddy, Chintam Nagendra, Cossette, Chantal, Gravel, Sylvie, Zeller, Matthias, Slobodchikova, Irina, Vuckovic, Dajana, Rokach, Joshua, Powell, William S.
• Format: Article
• Language: English
• Subjects: 5-Lipoxygenase products; Administration, Oral; Alkylation; Animals; Anti-Asthmatic Agents - administration & dosage; Anti-Asthmatic Agents - blood; Anti-Asthmatic Agents - pharmacokinetics; Anti-Asthmatic Agents - pharmacology; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; Anti-Inflammatory Agents, Non-Steroidal - blood; Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics; Anti-Inflammatory Agents, Non-Steroidal - pharmacology; Arachidonic Acids - antagonists & inhibitors; Arachidonic Acids - metabolism; Chemotactic Factors - antagonists & inhibitors; Chemotactic Factors - metabolism; Chiral analysis; Drug metabolism; Eicosanoids; Eosinophils - drug effects; Eosinophils - immunology; Eosinophils - metabolism; Female; Glucuronides - blood; Glucuronides - chemistry; Glucuronides - pharmacology; Granulocytes; Humans; Hydroxylation; Inactivation, Metabolic; Indoles - administration & dosage; Indoles - blood; Indoles - chemistry; Indoles - pharmacokinetics; Indoles - pharmacology; Inflammation; Keto Acids - administration & dosage; Keto Acids - blood; Keto Acids - chemistry; Keto Acids - pharmacokinetics; Keto Acids - pharmacology; Macaca fascicularis; Molecular Structure; Neutrophils - drug effects; Neutrophils - immunology; Neutrophils - metabolism; Receptors, Eicosanoid - agonists; Receptors, Eicosanoid - antagonists & inhibitors; Receptors, Eicosanoid - metabolism; Stereoisomerism
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2017.04.031

[Display omitted] We have developed a selective indole antagonist (230) targeting the OXE receptor for the potent eosinophil chemoattractant 5-oxo-ETE (5-oxo-6,8,11,14-eicosatetraenoic acid), that may be useful for the treatment of eosinophilic diseases such as asthma. In previous studies we identified ω2-oxidation of the hexyl side chain of racemic 230 as a major metabolic route in monkeys, but also obtained evidence for another pathway that appeared to involve hydroxylation of the hexyl side chain close to the indole. The present study was designed to investigate the metabolism of the active S-enantiomer of 230 (S230) and to identify the novel hydroxy metabolite and its chirality. Following oral administration, S230 rapidly appeared in the blood along with metabolites formed by a novel and highly stereospecific α-hydroxylation pathway, resulting in the formation of αS-hydroxy-S230. The chirality of α-hydroxy-S230 was determined by the total synthesis of the relevant diastereomers. Of the four possible diastereomers of α-hydroxy-230 only αS-hydroxy-S230 has significant OXE receptor antagonist activity and only this diastereomer was found in significant amounts in blood following oral administration of S230. Other novel metabolites of S230 identified in plasma by LC–MS/MS were αS,ω2-dihydroxy-S230 and glucuronides of S230 and ω2-hydroxy-S230. Thus the alkyl side chain of S230, which is essential for its antagonist activity, is also the major target of the metabolic enzymes that terminate its antagonist activity. Modification of this side chain might result in the development of related antagonists with improved metabolic stability and efficacy.